drugset
drugset / Trial / NCT05354323

NECVAX-NEO1 in Addition to Checkpoint Inhibitor in Patients With Solid Tumors

NCT05354323 ↗

Phase 1 Active not recruiting 6 enrolled NEC OncoImmunity AS
NaSingle-groupOpen-labelTreatment

Summary

NECVAX-NEO1 in addition to anti-PD-1 or anti-PD-L1 monoclonal antibody checkpoint inhibitor monotherapy in n=6 patients with solid tumors

Timeline

Start
2022-05-05
Primary completion
2025-12-31
Completion
2025-12-31

Drugs

EvaluationDrugModalityDoseRoute
Subject NECVAX-NEO1 Vaccine — Oral

Indications

No indication recorded.